NFT Technologies Inc. Announces Public Listing on NEO Exchange; Trading Begins Today Under Symbol "NFT"

VANCOUVER, British Columbia–()–NFT Technologies Inc. (NEO: NFT) (“NFT Tech” or the “Company“) is pleased to announce that the issued and outstanding common shares of the Company (the “Common Shares”) will commence trading today on the Neo Exchange Inc. (the “NEO”), under the ticker symbol “NFT”.

The Common Shares are qualified by the Company’s long-form final prospectus dated May 12, 2022 (the “Prospectus”) filed with the British Columbia Securities Commissions, a copy of which is available under the Company’s profile on SEDAR at

NFT Tech enables innovative connectivity to the emerging Web3 ecosystem including digital assets and the Metaverse. Our technology supports “play to earn” gaming, and we advise individual and corporate creators and platforms and work with them to support the development of innovative IP.

Wayne Lloyd, the Executive Chairman of NFT Tech, stated: “We are excited to welcome our new investors and be listing on the NEO. As a publicly traded company, NFT Tech will be able to accelerate its growth plans while continuing to contribute to the overall evolution of the NFT industry. We look forward to building deeper connections with brands, their consumers and the cryptocurrency ecosystem at large as these communities are embracing all the ways NFTs can change the digital and physical world experience for the better.”

About NFT Tech

NFT Tech is working in the NFT space of unique digital assets and environments to develop new technologies, invest in digital assets and meaningful engagement in the Metaverse, and advise creators and platforms in the space. The business of the Company is focused on three main business lines, including: (i) technology; (ii) investing; and (iii) consulting. NFT Tech is actively engaged in “play to earn” blockchain gaming, and is the founder of the GOAT Guild. For more information please visit

About the Neo Exchange Inc.

The NEO is Canada’s Tier 1 stock exchange for the innovation economy, bringing together investors and capital raisers within a fair, liquid, efficient, and service-oriented environment. Fully operational since June 2015, the NEO puts investors first and provides access to trading across all Canadian-listed securities on a level playing field. NEO lists companies and investment products seeking an internationally recognized stock exchange that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data.

Cautionary Note on Forward-Looking Information

This press release contains certain forward-looking statements within the meaning of applicable securities laws with respect to the Company. These forward-looking statements generally are identified by words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” and similar expressions. Forward-looking statements in this press release include statements relating to the completion and timing of the listing on the NEO; plans for accelerating growth; and the continued public acceptance of NFTs. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release including, without limitation, the risk factors described in the Prospectus. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Neo Exchange has not reviewed or approved this press release for the adequacy or accuracy of its contents.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.


NEW YORK, May 24, 2022 /PRNewswire/ — Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the “Fund”) announced today the final results of its transferable rights offering (the “Offer”), which expired at 5:00 PM Eastern Time on May 17, 2022 (the “Expiration Date”). 

The final subscription price per share of common stock (“Common Stock”) was $8.60, which was equal to 87% of the Fund’s net asset value per share of Common Stock at the close of trading on the NYSE American on the Expiration Date. The Offer will result in the issuance of 4,763,981 shares of Common Stock.  The gross proceeds of the Offer are expected to be approximately $40.9 million.  The shares of Common Stock subscribed for are expected to be issued on or about May 25, 2022.  The Fund will return to subscribing investors the full amount of any excess payments.

This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund’s investment objective, risks, charges and expenses carefully before investing. The Fund’s prospectus supplement and accompanying prospectus contain this and additional information about the Fund and additional information about the Offer, and should be read carefully before investing.

Inquiries regarding the Offer should be directed to the Fund’s Information Agent, Georgeson LLC, at 1-866-647-8872.

About Neuberger Berman High Yield Strategies Fund Inc. The Fund’s investment objective is to seek high total return (income plus capital appreciation). Under normal market conditions, the Fund invests at least 80% of its total assets in high yield debt (below investment grade) securities of U.S. and foreign issuers, and up to 20% of its total assets in other securities and financial instruments.

About Neuberger Berman

Neuberger Berman, founded in 1939, is a private, independent, employee-owned investment manager. The firm manages a range of strategies—including equity, fixed income, quantitative and multi-asset class, private equity, real estate and hedge funds—on behalf of institutions, advisors and individual investors globally. With offices in 25 countries, Neuberger Berman’s diverse team has over 2,500 professionals. For eight consecutive years, the company has been named first or second in Pensions & Investments Best Places to Work in Money Management survey (among those with 1,000 employees or more). In 2020, the PRI named Neuberger Berman a Leader, a designation awarded to fewer than 1% of investment firms for excellence in Environmental, Social and Governance (ESG) practices. The PRI also awarded Neuberger Berman an A+ in every eligible category for our approach to ESG integration across asset classes. The firm manages $447 billion in client assets as of March 31, 2022. For more information, please visit our website at

Statements made in this release that look forward in time involve risks and uncertainties. Such risks and uncertainties include, without limitation, the adverse effect from a decline in the securities markets or a decline in the Fund’s performance, a general downturn in the economy, competition from other closed end investment companies, changes in government policy or regulation, inability of the Fund’s investment adviser to attract or retain key employees, inability of the Fund to implement its investment strategy, inability of the Fund to manage rapid expansion and unforeseen costs and other effects related to legal proceedings or investigations of governmental and self-regulatory organizations.

Neuberger Berman Investment Advisers LLC
Investor Information
(877) 461-1899

SOURCE Neuberger Berman

DLA Piper Advises Edenor, the Largest Electricity Distribution Company in Argentina, on its Successful Debt Exchange Offer

NEW YORK, May 24, 2022 /PRNewswire/ — DLA Piper has advised Empresa Distribuidora y Comercializadora Norte S.A. (Edenor), the largest electricity distribution company in Argentina, on the successful exchange offer for Edenor’s 9.75% senior notes due 2022.

Edenor offered to exchange any and all of its outstanding US$98 million of 9.75% senior notes due 2022 (the old notes), for new 9.75% senior notes due 2025 (the new notes). As of the expiration date of the exchange offer on May 9, US$71.8 million in aggregate principal amount of old notes, representing 73.25% of the aggregate principal amount of old notes outstanding, had been tendered and accepted in the exchange offer. The transaction closed earlier this month.

The debt refinanced by the new bonds was allocated in accordance with social bond guidelines to refinance, in whole or in part, eligible projects designed to expand access to electricity in low income communities, encourage the efficient use of electricity and install electronic “smart” meters to more efficiently measure electricity usage.

“We are honored to have acted for Edenor on its debt exchange offer,” said DLA Piper partner Christopher Paci who led the team. “We are very pleased we could draw on the strength of our combined teams in New York and Buenos Aires to advise Edenor on this important liability management transaction.”

Working with Paci on this deal were partners Marcelo Etchebarne (New York), Alejandro NobliaJusto Segura and Nicolas Teijeiro (all of Buenos Aires); and associates Daiana Suk and Federico Vieyra (both of Buenos Aires).

In 2021, DLA Piper acted for Empresa de Energia del Cono Sur S.A. (Edelcos) in its tender offer for the publicly listed shares of Edenor on Bolsas y Mercados Argentinos and the New York Stock Exchange following Edelcos’ acquisition of a majority of Edenor’s voting shares.

DLA Piper has advised on numerous landmark transactions in Argentina in the last two years, including on liability management transactions for YPF S.A., in which the firm represented an ad hoc committee comprising some of the largest bondholders, and the Provinces of Buenos Aires, Mendoza, Entre Rios, Chaco, Chubut and Salta.

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.

About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising.


LEX Announces It Will Take Seattle's SOLIS Building Public In IPO

NEW YORK–()–After multiple successful IPOs in New York and other cities, LEX is taking another building public, this time in the highly in-demand market of Seattle. The building, SOLIS, is an award-winning multifamily and retail asset designed with sustainability in mind. This offering is available to the general public on the LEX platform starting today.

SOLIS is situated on Capitol Hill’s fast-growing and popular Pine-Pike corridor. The building is surrounded by a lively mix of restaurants, bars, and prime retail and entertainment venues; it also offers convenient proximity to major tech employers and Seattle’s largest universities. Located on 1300 East Pike Street, SOLIS is currently 100% leased and features top-tier tenants including Sonder, the next generation hospitality company known for curating award-winning accommodations around the world.

“We’re thrilled to partner with LEX and offer investors the opportunity to invest in SOLIS through their innovative model,” said Marc Coluccio, SolTerra Capital COO. “SOLIS’s location in one of Seattle’s most desirable neighborhoods, its high sustainability standards, and tenants make the asset a compelling investment. We’re excited to offer it to the market in this IPO.”

SOLIS is built to Passive House standards, designed to operate using substantially less energy and achieve significant cost savings. Additionally the property is exempt from paying property taxes on over 61% of its assessed value for ten years. Recently constructed, SOLIS is an award-winning six story mixed-use building with 34,260 square feet of total rentable space: 5,960 square feet across three retail units on the first floor, and 28,300 square feet across 45 residential units for rent on floors two through six.

“This new IPO represents a major step forward in LEX’s mission to democratize the $17 trillion U.S. commercial real estate market,” said Drew Sterrett, LEX Co-Founder and Co-CEO. “SOLIS will expand our innovative approach to commercial real estate investing to one of the most highly in-demand markets in the country.”

SOLIS is open to all U.S. investors, as with all investments offered through LEX. Investors can benefit from favorable tax treatment and receive their proportional shares of income distributions at the same rate as the owner, all while diversifying their portfolio.

Once the initial offering period ends, SOLIS will be assigned a ticker, and shares will trade during standard market hours. Shares can be purchased through any brokerage account and will trade on the secondary market, just like any other stock.

LEX’s first New York City building IPO, 286 Lenox Ave., is now trading under the ticker symbol TESLU. In February, LEX closed a $15 million Series A financing round led by PEAK6 Strategic Capital, a division of PEAK6 Investments. Other major venture capital investors included Khosla Ventures, Two Lanterns, MUFG Innovation Partners, and Gaingels.

About LEX

LEX is a new way to invest in real estate. LEX turns individual buildings into public stocks. Any U.S. investor can open a LEX account, browse opportunities in various asset classes such as multifamily and office buildings, and buy shares of individual buildings. As a shareholder, investors can earn income quarterly and can trade their shares on our public market whenever they need to exit (liquidity not guaranteed). Each building on LEX has a ticker symbol and stock chart. LEX opens up direct and tax advantaged ownership in an asset class that has previously been inaccessible to most investors. For more information, please visit

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.

MSP Recovery, Inc. Begins Trading on Nasdaq Under the Symbol “MSPR” on May 24, 2022

CORAL GABLES, Fla.–()–MSP Recovery, Inc. (“MSPR”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader and technology innovator, announced that its Class A Common Stock and warrants will begin trading on May 24, 2022 on Nasdaq under the symbol “MSPR” following today’s completion of a business combination with Lionheart Acquisition Corporation II (“LCAP”).

As previously announced, LCAP’s warrants, each to purchase one share of Class A Common Stock of MSPR at $11.50 per share, ceased trading after the market close today on the Nasdaq Capital Market under the symbol “LCAPW” and will begin trading tomorrow (May 24, 2022) on Nasdaq Global Market under the symbol “MSPRZ”.

Since announcing the business combination with LCAP in July 2021, with an enterprise value of approximately $32.6 billion, MSPR has developed additional revenue streams and as of December 31, 2021, MSPR’s portfolio included more than $1.5 trillion in billed amount (reflecting the full amount billed by a provider to a health plan or insurer), up more than 530% from $242 billion in 2020. MSPR’s portfolio included $364.4 billion in paid amount as of the same date (reflecting amounts actually paid to a provider from a health plan), up more than 520% from $58.4 billion in 2020. Over the same period, MSPR has seen a significant increase in interest from various entities in the healthcare industry. MSPR already has more than 150 assignors, and continues to grow its number of assignors.

“We’ve come a long way since I launched MSP Recovery more than eight years ago with one simple goal: to disrupt this country’s antiquated healthcare payment system and innovate solutions to help all Americans. MSPR has discovered that the ingestion and processing of healthcare data is substantially fragmented and flawed. This causes economic loss and prevents proper care and treatment, which can lead to serious mental or physical conditions, including loss of life,” said MSP Recovery Founder and CEO, John H. Ruiz.

“We developed a pioneering data analytics platform that efficiently identifies and uncovers historical waste, helps to support the long-term sustainability of Medicare and Medicaid programs, and recovers monies owed to hospitals, health insurance companies and medical providers, among many others,” he explained.

“We also launched LifeWallet Powered by MSP Recovery to help first responders and healthcare providers quickly and easily access patient medical histories when they’re needed most. The platform enables informed decision-making and improved patient care to help save lives,” said Mr. Ruiz.

“John and his team identified an innovative approach to a growing asset class that was previously accessible only to institutional investors,” said Ophir Sternberg, Chairman and CEO of Lionheart. “We’re thrilled to be part of unlocking this opportunity for a broader range of investors with the listing of MSP Recovery on Nasdaq.”

About MSP Recovery Inc.

Founded in 2014, MSP Recovery has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions, while innovating technologies to help save lives. For more information, visit:

Limitless X Goes Public, Completes Previously Announced Share Exchange With Bio Lab Naturals, Inc

LOS ANGELES, May 23, 2022 /PRNewswire/ — Bio Lab Naturals, (“the Company”) (OTCQB: BLAB) announced that the Company and the shareholders of Limitless X, a creative and empowering lifestyle agency that has launched numerous industry-leading products in the dietary and CBD supplement sectors, have completed their share exchange agreement effective May 20, 2022, resulting in Limitless X becoming a wholly owned and the principal operating subsidiary of the Company.

In connection with the share exchange the Company has issued to the equity holders of Limitless X common stock equaling approximately 90% of the Company on a fully diluted basis in exchange for all the shares of Limitless X. Concurrently with the share exchange Jas Mathur, the founder and principal shareholder of Limitless X, also purchased from Helion Holdings LLC 500,000 shares of the Company’s Class A Preferred Super Majority Voting Convertible Stock which at all times have a number of votes equal to 60% of all the issued the outstanding shares of common stock of the Company. Limitless X is a Nevada corporation formed in September 2021. 

The Company intends to change its name and will be filing for a ticker symbol change in the coming weeks.

Limitless X will continue to carry on Bio Lab Naturals’ business and core operations, including Prime Time Live, Inc., a Denver, CO-based company that provides clients with high-resolution mobile LED screens for entertainment, corporate, civic, and sporting events. 

“Today marks an important milestone for Limitless X,” said Jas Mathur, CEO of Limitless X, “Our mission is to launch products and services which make people look good and feel great. Operating as a public company, we are now able to increase our visibility and exposure within the capital markets, expand our brand recognition and provide our market opportunity to a wider investor audience. I look forward to this next step, of entering the public markets and turning Limitless X into a rapidly growing successful enterprise and a globally recognized household brand.”

Led by successful entrepreneur and venture capitalist Jas Mathur, Limitless X boasts an integrated direct-to-consumer model, memorable brands and superior products, and an ambassador network including A-list music stars, movie stars, athletes, and more. With this transaction, the Company anticipates expanding its global eco-system and continuing to provide unique product and service-oriented businesses within the Health & Wellness, Beauty & Skincare, and CBD industries.

About Jas Mathur
Jas Mathur is an investor, entrepreneur and venture capitalist who has developed multiple brands in the marketing, health and wellness spaces generating tens to hundreds of millions of dollars in revenue each year. The digital marketing and branding firm he founded, Limitless, has launched multiple industry leading products in the dietary and CBD supplement sectors. He is a trendsetter with more than seven million Instagram followers and frequently collaborates with leaders in the sports and entertainment industries.

About Limitless X
Limitless X is a creative and empowering lifestyle agency specializing in the full spectrum of digital advertising and marketing. The Company has a global eco-system with three verticals and a series of industry leading product and service-oriented businesses within each, focused on the Health & Wellness, Beauty & Skincare, and CBD Industry. 

Forward-Looking Statement

This press release includes “forward-looking statements” within the meaning of U.S. federal securities laws. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. The Company cautions that these statements are based on management’s current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside of the control of the Company, that could cause actual results and events to differ materially from the statements made herein. Such risks and uncertainties include, but are not limited to, disruption in distribution or sales and/or decline in sales due to the current market conditions caused by the coronavirus pandemic. For a more detailed discussion of these and other risks that could affect our operating results, see the Company’s reports filed with the Securities and Exchange Commission. The Company’s actual results could differ materially from those contained in the forward-looking statements. The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Limitless X

PETRÓLEOS DEL PERÚ – PETROPERÚ S.A. Commences Consent Solicitation in connection with its outstanding 4.750% Notes Due 2032 (CUSIP No. 716564 AA7 (144A)/P7808B AA5 (REGS) (ISIN No. US716564AA72 (144A)/USP7808BAA54 (REGS)) and 5.625% Notes Due 2047 (CUSIP No. 716564 AB5 (144A)/P7808B AB3 (REGS) (ISIN No. US716564AB55 (144A)/USP7808BAB38 (REGS))

LIMA, Perú, May 23, 2022 /PRNewswire/ — Petróleos del Perú – Petroperú S.A. (the “Company“) today announced that, upon the terms and subject to the conditions set forth in the Consent Solicitation Statement dated as of May 23, 2022 (the “Consent Solicitation Statement“), it is soliciting consents (“Consents“) from the Holders of its outstanding (i) 4.750% Notes Due 2032 (the “2032 Notes“) and (ii) 5.625% Notes Due 2047 (the “2047 Notes” and, collectively with the 2032 Notes, the “Notes” and each a “Series“) to certain proposed amendments (the “Proposed Amendments“) to the indentures governing the Notes (the “Consent Solicitation“).

The purpose of the Consent Solicitation and the Proposed Amendments is to extend the timeframe within which the Company must deliver its audited financial statements for the 2021 fiscal year pursuant to the indentures governing the Notes. The Proposed Amendments would also provide that failure by the Company to deliver its audited financial statements for the 2021 fiscal year by the applicable deadline would constitute an Event of Default and not be subject to a cure period. The Consent Solicitation will expire at 5:00 p.m., New York City time, on May 31, 2022, unless extended by the Company (such time and date, as the same may be extended, the “Expiration Time“).

Subject to certain conditions, including satisfaction of the CESCE Amendment Condition, which are more fully described below, if the Tabulation and Information Agent for the Consent Solicitation receives validly delivered Consents from Holders representing (i) a majority of the aggregate principal amount of the 2032 Notes outstanding and (ii) a majority of the aggregate principal amount of the 2047 Notes outstanding (the “Requisite Consents“) on or prior to the Expiration Time and those Consents are not revoked on or prior (but not after) the earlier of (a) the first time and date on which the Requisite Consents are received and (b) 5:00 p.m., New York City time, on May 31, 2022, unless extended by the Company (such time and date, as the same may be extended, the “Revocation Deadline“), the Company will pay to each Holder who has validly delivered and not revoked its Consent a fee in cash (the “Consent Fee“) equal to US$1.50 for each US$1,000 principal amount of Notes in respect of which the Company accepted its Consent.

The Consent Fee will not become payable with respect to any Series unless (i) the Requisite Consents have been received on or prior to the Expiration Time (and not revoked on or prior to the Revocation Deadline) with respect to both Series; (ii) supplemental indentures documenting the Proposed Amendments have been executed by the Company and The Bank of New York Mellon, as indenture trustee, (iii) the CESCE Amendment Condition is satisfied and (iv) certain other general conditions described in the Consent Solicitation Statement are satisfied or waived by the Company.

The Proposed Amendments contained in the Supplemental Indentures will not become operative unless all conditions to the Consent Solicitation are satisfied or, where possible, waived by Petroperú, and payment of the Consent Fee is made.

Prior to the date hereof, the Company sent an amendment request to lenders under that certain facility agreement among the Company, as borrower, certain lenders, and Deutsche Bank, S.A.E., as administrative agent, guaranteed by Compañía Española de Seguros de Crédito a la Exportación, S.A., Compañía de Seguros y Reaseguros, S.M.E., the Spanish Export Credit Agency CESCE (such guaranteed facility agreement, the “CESCE Facility Agreement“), to extend the timeframe within which the Company must deliver the audited consolidated financial statements for the 2021 fiscal year under the CESCE Facility Agreement to September 30, 2022. The effective amendment of the CESCE Facility Agreement is one of the conditions set forth in the Consent Solicitation Statement (the “CESCE Amendment Condition“).

Following the amendment request, the Company has proactively coordinated with CESCE and the administrative agent to procure that a majority of the lenders under the CESCE Facility Agreement, representing the required lenders thereunder, agree to the requested amendment.  The Company currently expects that the CESCE Facility Agreement will be formally amended thereby satisfying the CESCE Amendment Condition in the next several days.  There is no assurance, however, that the CESCE Facility Agreement will be formally amended as requested by the Company or that the CESCE Amendment Condition will be satisfied.

The Company has the right, in its sole discretion, to amend or terminate the Consent Solicitation at any time.

Citigroup Global Markets Inc., HSBC Securities (USA) Inc., and Santander Investment Securities Inc. are acting as Solicitation Agents for the Consent Solicitation.  The Tabulation and Information Agent is Global Bondholder Services Corporation.

Requests for documentation should be directed to Global Bondholder Services Corporation at (855) 654-2014.  Questions regarding the Consent Solicitation should be directed to the Solicitation Agents at 212 723 6106 (for Citigroup), +1 (888) HSBC-4LM (for HSBC), or +1 (212) 940-1442 (for Santander). 

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. 

None of the Company, the Solicitation Agents, the Tabulation and Information Agent makes any recommendation as to whether holders should Consent or refrain from Consenting to the Proposed Amendment. Holders must make their own decision as to whether to deliver their Consents.

About Petroperu:
Petróleos del Perú – Petroperú S.A. established in 1981 as a Public Limited Company pursuant with Legislative Decree No 43 (founded in 1969), Petroperú is the largest hydrocarbon corporate entity in Peru in terms of total sales and the largest enterprise of the Peruvian sovereign (100% owned by Peru). It is also Peru’s second largest refiner in terms of refining volume capacity and forms a critical part of the country’s energy infrastructure and economy. It has the largest distribution network for crude oil and refined products in the country, and it is the sole provider of refined products to certain areas of Peru. It is also the owner and operator of Peru’s main oil pipeline, the “Norperuano Pipeline,” which connects the crude oil production fields in the northern rainforest of Peru with its facilities in the Port of Bayovar near its Talara Refinery. Its business is comprised primarily of midstream and downstream petroleum activities, including the refining and blending of crude and intermediate hydrocarbon products, the distribution and sale of refined products through its wholesale distributors and associated retail service stations and direct sales, the transportation of crude through the Norperuano Pipeline, and the leasing of certain of its facilities to third parties. Petroperú also has a presence in the upstream sector.


Cautionary Note Concerning Forward-Looking Statements 
This Consent Solicitation Statement contains statements that are or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those described in such forward-lookingforward-looking statements included in this Consent Solicitation Statement. You are cautioned not to place undue reliance on such forward-looking statements, which speak only as of their dates. The Company disclaims any obligation or undertaking to update publicly or revise any forward-looking statement contained in this press release or the Consent Solicitation Statement, whether as a result of new information, future events or otherwise. Future events or circumstances could cause actual results to differ materially from historical results or those anticipated.

SOURCE Petróleos del Perú – Petroperú S.A.

Athora Netherlands N.V. announces Tender Offer for any and all of its US$ 575,000,000 Subordinated Notes


AMSTELVEEN, Netherlands, May 23, 2022 /PRNewswire/ — Athora Netherlands N.V. (formerly named VIVAT N.V.) (the Offeror) has today launched an offer to holders of its outstanding notes detailed below (the Notes) to tender any and all such Notes for purchase by the Offeror for cash at the Purchase Price, on the terms and subject to the conditions described in the Tender Offer Memorandum dated 23 May 2022 (the Tender Offer Memorandum), including satisfaction or waiver of the New Financing Condition (as defined below) and the “Offer and Distribution Restrictions” below and the related notice of guaranteed delivery (such invitation, the Offer).

The full launch announcement in respect of the Offer, which contains further details about the Offer, is available from the website of the Offeror at Copies of the Tender Offer Memorandum are (subject to distribution restrictions) available from the Tender Agent as set out below. Capitalised terms used in this announcement but not defined have the meanings given to them in the Tender Offer Memorandum.

Description of Notes

ISIN/ Common Code

Principal Amount Outstanding


First Call Date

Purchase Price

Acceptance Amount

US$ 575,000,000 Fixed to Fixed Rate Undated Subordinated Notes

XS1717202490 / 171720249

US$ 575,000,000

per cent.

16 November 2022

per cent.

Any and all

Rationale for the Offer

The purpose of the Offer and the planned issuance of the New Notes is to proactively manage the Offeror’s upcoming debt redemption and to optimize its funding costs.

Irrespective of the outcome of the Offer and subject to applicable law, the Offeror intends to continue to consider future optional redemption rights in respect of the Notes that are not tendered and accepted pursuant to the Offer on an economic basis, taking into account the prevailing circumstances at the relevant time including prevailing market conditions, current and future regulatory value, relative funding value of the Notes, rating agency considerations and any regulatory developments.

New Financing Condition

The Offeror has today announced its intention to issue new euro-denominated subordinated (Tier 2) notes (the New Notes), subject to market conditions. The purchase of any Notes by the Offeror pursuant to the Offer is subject to, without limitation, the successful completion (in the sole determination of the Offeror) of the issue of the New Notes (the New Financing Condition).

Priority in allocation of New Notes

A Noteholder that has validly tendered, or indicated its firm intention to tender, its Notes for purchase pursuant to the Offer and wishes to subscribe for New Notes in addition to tendering Notes for purchase pursuant to the Offer may, after having made a separate application for the purchase of such New Notes to a Dealer Manager (in its capacity as a joint lead manager of the issue of the New Notes), at the sole and absolute discretion of the Offeror, receive priority in the allocation of the New Notes, subject to the issue of the New Notes. When considering allocation of the New Notes, the Offeror intends to give preference to those Noteholders who, prior to such allocation (which may be before the Expiration Deadline), have tendered, or indicated to the Offeror or either of the Dealer Managers their firm intention to tender their Notes and subscribe for New Notes. Any allocation of the New Notes may, subject to the sole and absolute discretion of the Offeror, be less than, equal to or greater than the aggregate principal amount of the Notes tendered or firmly indicated to be tendered.

Indicative Timetable for the Offer

The Offer commences today and the Expiration Deadline shall be 4.00 p.m. (London time) on Tuesday, 31 May 2022. The Results will be announced as soon as reasonably practicable after the Expiration Deadline on Wednesday, 1 June 2022. The deadline for delivery of Notes tendered by guaranteed delivery procedures shall be 4.00 p.m. (London time) on Thursday, 2 June 2022. The Settlement Date of the Offer is expected to be Tuesday, 7 June 2022. The Guaranteed Delivery Settlement Date is expected to be Wednesday, 8 June 2022

BNP Paribas and NatWest Markets N.V. are acting as Dealer Managers for the Offer and Kroll Issuer Services Limited  is acting as Tender Agent (Telephone: +44 20 7704 0880; Attention: Owen Morris; Email: [email protected]; Website:

This announcement is released by Athora Netherlands N.V. and contains information that qualified as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), encompassing information relating to the Offer described above. For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is made by Jim van Hees, Interim Chief Financial Officer, on behalf of Athora Netherlands N.V.

DISCLAIMER This announcement must be read in conjunction with the Tender Offer Memorandum. This announcement and the Tender Offer Memorandum contain important information which should be read carefully before any decision is made with respect to the Offer. If you are in any doubt as to the contents of this announcement or the Tender Offer Memorandum or the action you should take, you are recommended to seek your own financial, tax and legal advice, including as to any tax consequences, immediately from your broker, bank manager, solicitor, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to participate in the Offer. None of the Offeror, the Dealer Managers or the Tender Agent is providing Noteholders with any legal, business, tax or other advice in this announcement or the Tender Offer Memorandum. Noteholders should consult with their own advisers as needed to assist them in making an investment decision and to advise them whether they are legally permitted to participate in the Offer.

Any investment decision to purchase any New Notes should be made solely on the basis of the information contained in the final offering memorandum to be dated on or around 27 May 2022 prepared in connection with offering, issue and listing of the New Notes (the Offering Memorandum) and no reliance is to be placed on any representations other than those contained in the Offering Memorandum. Subject to compliance with all applicable securities laws and regulations, the Offering Memorandum is available from the Dealer Managers (in their capacities as joint lead managers of the issue of the New Notes) on request. The New Notes are not being, and will not be, offered or sold in the United States. Nothing in the Tender Offer Memorandum constitutes an offer to sell or the solicitation of an offer to buy the New Notes in the United States or any other jurisdiction. Securities may not be offered, sold or delivered in the United States absent registration under, or an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the Securities Act). The New Notes have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or delivered, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. Persons, except in transactions exempt from the registration requirements of the Securities Act.

Compliance information for the New Notes:  UK MiFIR professionals/ECPs only – eligible counterparties and professional clients only (all distribution channels). MiFID II professionals/ECPs only – eligible counterparties and professional clients (all distribution channels).

No action has been or will be taken in any jurisdiction in relation to the New Notes to permit a public offering of securities. The offer and sale of the New Notes will be subject to the selling restrictions specified in the Prospectus.

SOURCE Athora Netherlands N.V.

SmartSens Goes Public on Shanghai Stock Exchange and Sees Shares Surge on the First Trading Day

SmartSens Technology (Shanghai) Co., Ltd. (Stock Code: 688213) is a high-performance CMOS image sensor (CIS) chip design company. It is headquartered in Shanghai and has research centers in many cities around the world.

SmartSens has been dedicated to pushing forward the frontier of imaging technology and growing in popularity among customers since it was established. SmartSens’ CMOS image sensors provide advanced imaging solutions for a broad range of areas such as surveillance, machine vision, automotive and cellphone cameras.

SmartSens is committed to continuous innovation of products and fueling growth in numerous industries by delivering a more comprehensive portfolio of image sensors.

SOURCE SmartSens

Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering

SAN DIEGO, May 20, 2022 /PRNewswire/ — Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71,000,000 shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $0.75, less underwriting discounts and commissions, and each pre-funded warrant and accompanying common warrant are being offered at a combined public offering price of $0.749, less underwriting discounts and commissions. The pre-funded warrants have an exercise price of $0.001 per share. The common warrants have an exercise price of $0.75 per share, are exercisable immediately, and will expire five years following the date of issuance. All of the shares of common stock, pre-funded warrants and accompanying warrants being offered in the offering are being sold by Evofem. The gross proceeds from the offering to Evofem, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received upon exercise of the common warrants, are expected to be approximately $26.6 million.  The offering is expected to close on or about May 24, 2022, subject to satisfaction of customary closing conditions.

Evofem intends to use the net proceeds from the offering for the continuation of commercialization activities related to its commercial product, Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, the continuation of its registrational Phase 3 clinical trial “EVOGUARD”, which is evaluating Phexxi for two potential new indications, the prevention of chlamydia and gonorrhea in women, and related development activities, and other general corporate purposes and other capital expenditures.

Piper Sandler & Co. is acting as sole book-running manager for the offering.

The securities described above are being offered by Evofem pursuant to a shelf registration statement on Form S-3 (File No. 333-258321) that was previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on August 5, 2021. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and, when available, will be available on the SEC’s website at and may also be obtained by contacting Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, or by telephone at (800) 747-3924, or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Evofem Biosciences

Evofem Biosciences, Inc. (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. Evofem’s first FDA-approved product, Phexxi® (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Top-line data is expected in the second half of 2022 from the registrational Phase 3 EVOGUARD trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women, two potential new indications.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including without limitation statements related to the offering of securities by Evofem such as, statements related to the consummation of the offering, the exercise of the warrants to be issued in the offering, the intended use of proceeds, the potential terms of the offering, and the timing of the registrational Phase 3 EVOGUARD trial. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including satisfaction of customary closing conditions related to the offering, the future cash exercise of the warrants, market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences’ assets and business, are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Investor Contact

Amy Raskopf 
Evofem Biosciences, Inc. 
[email protected] 
Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.